Noam Krantz
Senior Vice President at Guardant Health
Noam Krantz
Senior Vice President at Guardant Health
San Francisco, California
Overview
Work Experience
Senior Vice President
2022 - Current
Using the years of experience I have in Mergers & Acquisitions, corporate development, and venture investing to accelerate growth in cancer screening and therapeutics and precision medicine. Guardant is THE leader in precision medicine and our goal is to conquer cancer globally. We are creating innovative platforms focused on early stage development of diagnostics, therapeutics and wellness.
Board Member
2022
Helping to raise awareness and raise money for the American Heart Association
Investor
2022
Deep value investor with a focus in the medical device and technology market. Side interest in the oil and gas market. Focus on situations where change is underway and there is a clear mismatch between company prospects and current Wall Street perception and/or lack of coverage. I take personally meaningful positions in companies and offer strategic help where appropriate to help close this mismatch gap. For private companies, I have offered my expertise in creating best in class medical device companies and advised on how to maximize positioning for strategic investment and subsequent exit to strategics or public markets.
Vice President, Business Development, Strategy and Venture
2022 - 2022
- Led Business Development strategy and general strategy for all business units - Advised on plans to develop new corporate venture group for the company
Vice President, Venture Investing
2020 - 2022
- Venture Investor specializing in all ares of medical technology - Board member with specific expertise in audit, compensation, M&A, and strategy - Boards: Procept Biorobotics, Osteal Therapeutics, RefleXion, Docspera, MedTech Innovator (Board Secretary), Visus Therapeutics, Neptune Medical, EyeCareLive, MedCrypt - Other investments: Histosonics, Inspire Medical, Neotract, Lifebond, Auris Robotics
World Wide Vice President, Business Development
2010 - 2020
Led global business development strategy and licensing/acquisitions execution - Focus on Surgery, Oncology, Esophageal, Metabolics/Obesity, and all core platforms (Endomechanical, Wound Closure, Advanced/Core Energy, Interventional Oncology, Biosurgery) Led Medical Device Sector Deal Committee (sector represents ~$30 billion of revenue) - Developed cross sector strategies and review guidelines - Set format and agenda for deal pipeline review, manage monthly meetings Member of the Ethicon Executive Leadership Team Managed team of 6-10 Business Development Directors and Managers Member of the Asia Pacific Medical Device Executive Leadership Team (2012-2015) - Led Emerging Markets business development - Restructured organizations in Europe and Asia Pacific - Made investments to accelerate access to Chinese device innovation Founding sponsor of the Millennial Enterprise Resource Group - Group was developed to generate communication between senior leadership and the millennial generation as well as to create intergenerational contact across Ethicon - Established the group to succeed through several successive leadership changes Completed Accelerate Enterprise Leadership program (2012) - Recommendation to launch over-the-counter pain medicine in Emerging Markets beginning with product sampling in Indonesia - Primary market research conducted in person
Vice President, Corporate Development
2006 - 2010
Member of Executive Leadership Team, company officer and one of four direct reports to the CEO Advised management and Board on M&A/licensing strategies as well as general strategy - Presented to Board of Directors (BOD) on license and acquisition transactions and strategic alternatives - Developed and presented to BOD industry strategic analyses and competitive landscaping - Counseled CEO, CFO and General counsel on investor relations activity and capital structure decisions - Wrote all quarterly 8K’s and investor call scripts - One of three member team that determined annual guidance - Wrote Wall Street Investor Relations presentations - Attended all one-on-one meetings with investors during road shows and conferences - Led the sale to Johnson & Johnson including presenting to BOD, ascertaining valuation, managing due diligence, creating merger agreement, leading FTC/NYSE process, and researching all strategic alternatives Rung the opening bell of the New York Stock Exchange Responsible for various integration activities, distributor acquisitions and general business development strategy within Ethicon Franchise after purchase by Ethicon
Senior Manager, Strategy and Corporate Development, Investor Relations
2004 - 2006
Advised CEO, CFO and business heads on M&A and licensing strategies - Key member of the team that led the sale of the company to Allergan, which resulted in a combination that grew the business by almost 5 times in revenue - High water mark for midcap company exit at 27 times EBITDA - Managed transaction during competitive public company bidding situation and led due diligence, valuation determination, strategic alternatives analysis, and the rigorous FTC process Counseled CFO on capital structure decisions Rung the opening bell of NASDAQ Provided analytical support and coverage to CFO for investor relations activities - Wrote IR presentations - Scripted quarterly analyst calls - Attended most one-on-one meetings with investors and Wall Street conferences
Associate Investment Banker
2001 - 2004
Executed mergers and acquisitions and corporate finance transactions Advised client management on acquisition, growth and financial strategies Aided client management with transaction activities including positioning in the capital markets, presentations to their BOD, presentations to the investment community and valuation Built internal due diligence memoranda outlining clients’ strategies, industry dynamics and financial strength (contained independent analysis to support/refute management’s financial models) Modeled, pitched and executed transactions involving hybrid financial products such as convertible securities and equity and fixed income derivatives